Quick answer
How is a peptide like hexarelin made? Hexarelin, His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2, is a six-residue linear peptide and is made by Fmoc solid-phase peptide synthesis: the chain is built from the C-terminus on an amide-forming resin, residues are added one at a time, the finished peptide is cleaved with trifluoroacetic acid, purified by reversed-phase HPLC and freeze-dried. Each step leaves characteristic impurities, which is why HPLC purity and identity data matter. This page describes general chemistry, not any supplier's process. The V8 vial is 5 mg, ≥98% HPLC. For laboratory research use only; not for human consumption.
A six-residue peptide is among the easiest things to make by solid-phase chemistry, and that is exactly why its manufacture is worth understanding. Short chains are usually made well, but "usually" depends on a few specific chemical risks, and hexarelin has several of them: two D-amino acids, a methylated tryptophan, a second tryptophan that is easily damaged during acid cleavage, a histidine prone to racemization and a C-terminal amide that dictates the choice of resin. This guide walks through the route in order. It describes general peptide chemistry and not the process of any particular supplier. The compound is supplied for laboratory research use only.
The target molecule
The hexarelin product page gives the formula C47H58N12O6 and the sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2. The features that shape the synthesis are listed below.
| Position | Residue | Synthetic consideration |
|---|---|---|
| 6 (C-terminal) | Lys-NH2 | Amide at the C-terminus; the ε-amino group needs side-chain protection during assembly |
| 5 | D-Phe | Non-natural D-isomer; supplied as an Fmoc-protected building block |
| 4 | Trp | Indole ring is sensitive to acid-generated cations during cleavage |
| 3 | Ala | Unhindered; couples easily |
| 2 | D-2-methyl-Trp | Non-natural, bulky; the methyl group can slow coupling of the next residue |
| 1 (N-terminal) | His | Imidazole side chain needs protection; the residue is prone to racemization when activated |
Step 1: choose the resin and anchor the first residue
Merrifield introduced solid-phase peptide synthesis in 1963, attaching the C-terminal residue to an insoluble support so that excess reagents and by-products could be washed away after every step (Merrifield, 1963). The choice of support sets the C-terminal group. Hexarelin ends in an amide, so the synthesis starts on an amide-forming linker, in practice a Rink-type or similar resin whose acid cleavage releases a primary amide. A resin that releases a free carboxylic acid would produce a different molecule altogether. The first residue, Fmoc-Lys with an acid-labile protecting group on its side chain, is coupled to the resin before chain extension begins.
Step 2: build the chain from C-terminus to N-terminus
Fields and Noble reviewed the Fmoc strategy that now dominates the field (Fields and Noble, 1990). Each cycle has the same four parts:
- Deprotection. A secondary-amine base removes the Fmoc group and exposes the amino group of the growing chain.
- Wash. Solvent removes the base and the cleaved by-product.
- Coupling. The next Fmoc-amino acid, activated with a coupling reagent, is added in excess.
- Wash and check. Excess reagent is removed, and a colorimetric test can confirm that free amines are gone.
Coupling in excess drives each step toward completion, but no step is perfectly efficient. For a hexapeptide with a methylated D-tryptophan at position 2, the coupling of the third residue onto that hindered amine is a likely spot for incomplete reaction. Chemists commonly respond with a longer coupling time, a repeat coupling or a more reactive activator. If the repeat is skipped, the product contains a deletion sequence missing alanine.
Step 3: the histidine problem
Histidine is the residue most often discussed in connection with racemization, because its imidazole ring can assist loss of stereochemistry at the α-carbon when the carboxyl group is activated. Hexarelin has histidine at the N-terminus, which is the last residue added, so it is coupled once and then not exposed to repeated activation. The practical controls are a side-chain protecting group on the imidazole, a coupling method that limits the time the residue spends in its activated form, and an analytical method that can detect the D-His diastereomer. A diastereomer has the same mass as the target, which is why mass alone cannot reveal it, and why chromatographic resolution matters.
Step 4: cleavage and the tryptophan problem
When assembly is complete, trifluoroacetic acid (TFA) releases the peptide from the resin and removes the side-chain protecting groups. This step generates reactive cations from the protecting groups, and these attack electron-rich side chains. Tryptophan is the classic victim. Chemists include scavengers in the cleavage cocktail to capture the cations before they reach the indole ring, and a hexarelin synthesis with two tryptophan-derived residues needs this care in particular. Alkylated or oxidized tryptophan species are typical by-products of poor scavenging.
| Cleavage-related issue | Origin | Typical analytical sign |
|---|---|---|
| Tryptophan alkylation | Cations from protecting groups attack the indole | Peaks with higher mass than the target |
| Tryptophan oxidation | Air, light or peroxides during work-up | Mass shifts of +16 or +32 Da |
| Incomplete deprotection | Short cleavage time or weak cocktail | Late-eluting peaks carrying a protecting group |
| Residual TFA | Counterion bound to basic side chains | Lower net peptide content than HPLC purity suggests |
Step 5: purification, salt and freeze-drying
The crude peptide is dissolved and purified on a reversed-phase HPLC column; fractions are analyzed, and those meeting the specification are pooled and lyophilized. The product is the trifluoroacetate salt unless an ion exchange step has been done. That detail is not cosmetic: Cornish and colleagues reported that trifluoroacetate, a contaminant in purified proteins, inhibited proliferation of osteoblasts and chondrocytes in culture (Cornish and colleagues, 1999). A study with a proliferation or viability endpoint should therefore ask which counterion a lot carries and include a salt-matched control. The product page does not state a counterion. How freeze-drying works is covered in what is lyophilization.
Why short peptides are made this way
Muttenthaler and colleagues reviewed trends in peptide drug discovery, including the use of chemical modification and non-natural building blocks (Muttenthaler and colleagues, 2021). Chemical synthesis places such residues wherever the designer wants them, and that freedom is what produced hexarelin's two D-residues and its 2-methyltryptophan, none of which a bacterial expression system could install. It is also why impurity profiles of synthetic peptides are defined by chemistry, not by biology: deletion, truncation, protecting-group and oxidation products, and stereoisomers, rather than host-cell proteins. When you read an analytical report, ask which of those classes the method could actually have seen.
What the finished vial can and cannot tell you
Vergote and colleagues discussed the specifications that regulators expect for peptide drugs, including identity, purity, impurity profiling and content (Vergote and colleagues, 2009). Research-grade material is not held to that standard, but the framework is a useful checklist for a laboratory deciding how much to trust a label. It separates four questions that a single "purity" number blurs together.
| Question | Which measurement answers it | What a single HPLC percentage does not say |
|---|---|---|
| Is it the right molecule? | Identity confirmation, for example by measured mass or sequence-level data | A chromatographic peak is not an identity proof |
| How much of the signal is the main peak? | HPLC area percentage | Does not count material that does not absorb at the detection wavelength |
| How much peptide is in the vial? | Net peptide content | HPLC purity says nothing about counterion and water mass |
| Are stereoisomers present? | A method that separates diastereomers | D-His or D/L swaps at other positions may co-elute under a standard gradient |
The V8 page states ≥98% purity by HPLC for hexarelin; batch certificates, where published, are in the COA library. The reading guide how to read a COA and the page on understanding HPLC purity explain the terms, and hexarelin purity testing applies them to this molecule. If a lot's certificate is not published, record that fact; do not infer it.
Bench consequences of the chemistry
- Protect from light and air. The two tryptophan-derived residues are the likely oxidation sites.
- Use the formula for concentration. c = m / V; moles n = m / M with M from the formula. The calculator handles the unit conversions.
- Assume net content is lower than vial mass. If exact molarity matters, measure it by amino acid analysis or UV after reconstitution, using the tryptophan absorbance at 280 nm.
- Keep reconstitution gentle. See how to reconstitute a lyophilized peptide.
- Match controls to the counterion question. In sensitive cell assays use a salt-matched control.
Limits of this account
This page describes textbook peptide chemistry and uses the structure from the product page to say where the risks lie. It does not claim that any particular lot contains any particular impurity, and it does not describe a specific manufacturer. Further reading on the molecule is in what is hexarelin and the hexarelin research overview. Material is listed in the research catalog for laboratory research use only.
Related reading
- Hexarelin research overview
- What is hexarelin?
- Hexarelin purity testing
- Understanding HPLC purity
- Where to buy hexarelin for research
Frequently asked questions
How is hexarelin synthesized?
By Fmoc solid-phase peptide synthesis on an amide-forming resin, followed by cleavage with trifluoroacetic acid, reversed-phase HPLC purification and lyophilization. This describes general chemistry, not a specific supplier's process.
Why does the C-terminal amide matter for synthesis?
It determines the resin. An amide-forming linker releases a primary amide on cleavage, whereas a standard acid-forming resin would give a different molecule.
Which residues are hardest in hexarelin?
The coupling after the bulky D-2-methyl-tryptophan, the racemization-prone histidine, and the tryptophan residues that are vulnerable during acid cleavage.
What is a deletion sequence?
A peptide missing one residue because a coupling step was incomplete. It is lower in mass than the target and usually elutes earlier on reversed-phase HPLC.
Why can mass alone not detect a stereoisomer?
A diastereomer has the same mass as the target. Chromatographic separation or another stereochemically sensitive method is needed.
What does trifluoroacetate have to do with cell assays?
Peptides are usually delivered as TFA salts, and trifluoroacetate has been reported to inhibit proliferation of some cultured cell types. Sensitive assays should use a salt-matched control.
Does 98% HPLC purity equal 98% peptide?
No. It is an area percentage of the chromatogram. Net peptide content is lower because counterions and water also contribute to vial mass.
What are the hexarelin vial details?
The product page lists a 5 mg lyophilized powder, ≥98% purity by HPLC, formula C47H58N12O6, stored at 2–8 °C with −20 °C for long-term holding.
How do I find a lot's certificate?
Certificates are listed in the COA library where they have been published. Match the lot number on the vial to the entry and record the result.
How do I calculate concentration after reconstitution?
Divide the vial mass by the diluent volume (c = m / V). Use the reconstitution calculator for unit conversions, and measure net content if exact molarity is required.
Related reading: Hexarelin and IGF-1: What Preclinical Studies Report, Hexarelin Dose Reporting in Published Animal Studies, Hexarelin Half-Life and Stability: What Is Published.
References
- Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc. 1963;85(14):2149-2154. doi:10.1021/ja00897a025
- Fields GB, Noble RL. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int J Pept Protein Res. 1990;35(3):161-214. doi:10.1111/j.1399-3011.1990.tb00939.x
- Cornish J, Callon K, Lin C, et al. Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes. Am J Physiol. 1999;277(5):E779-E783. doi:10.1152/ajpendo.1999.277.5.E779
- Vergote V, Burvenich C, Van de Wiele C, De Spiegeleer B. Quality specifications for peptide drugs: a regulatory-pharmaceutical approach. J Pept Sci. 2009;15(11):697-710. doi:10.1002/psc.1167
- Muttenthaler M, King GF, Adams DJ, Alewood PF. Trends in peptide drug discovery. Nat Rev Drug Discov. 2021;20(4):309-325. doi:10.1038/s41573-020-00135-8
